Home

Data from the BIOSOLVE-IV trial, presented at the Transcatheter Cardiovascular Therapeutics annual meeting (TCT 2021, 4–6 November, Orlando USA and virtual), demonstrate the superiority of the Magmaris (Biotronik) sirolimus-eluting bioresorbable magnesium scaffold with regard to probable or definite scaffold thrombosis compared to a historical control group of the Absorb (Abbott) bioresorbable scaffold.

The full-cohort one-year results confirm the safety and performance of the Magmaris scaffold in a larger cohort, Biotronik said in a press release. Of particular note is the target lesion failure rate of 5% and a definite/probable scaffold thrombosis rate of 0.8% at 12 months, confirming the safety profile from the first cohort with 1,075 patients. The new data was presented by Johan Bennett, coronary interventionalist at University Hospitals Leuven, Leuven, Belgium.

“The results of the BIOSOLVE-IV study confirm that the Magmaris scaffold is safe and comparable to leading second-generation drug-eluting stents on the market. Importantly, the Magmaris scaffold also proves, for the first time, powered superiority to the Absorb scaffold for definite and probable scaffold thrombosis, an important landmark after the Absorb scaffold raised concerns with notably high rates of scaffold thrombosis compared to contemporary drug-eluting stents,” said Bennett, one of the registry’s principal investigators. “We are excited to see continuous low target lesion failure rates for this bioresorbable scaffold—now in larger and more diverse patient groups.”

BIOSOLVE-IV is an international, single arm, multicentre registry conducted in more than 80 centres in 23 countries in Europe, Asia, Africa, Australia and New Zealand. The registry includes 2,066 patients with a maximum of two single de novo lesions. BIOSOLVE-IV’s patient population encompasses N-STEMI patients, diabetic patients and more complex B2/C lesions, for whom a first cohort subgroup analysis at one-year follow-up was presented at TCT 2020. Follow-up is scheduled up to five years and the primary outcome is target lesion failure (TLF) at 12 months.

The recent positive outcomes complement previous BIOSOLVE-IV results such as the first cohort’s promising 12-month data as well as data presented at the EuroPCR 2021 meeting (18–20 May, virtual), showing no increase in scaffold thrombosis between 12-month and 24-month follow-ups.

“This full cohort data of a broad patient population including more challenging indications such as NSTEMI, demonstrate that the Magmaris RMS is a safe and effective therapy option,” commented Alexander Uhl, president of Vascular Intervention at Biotronik. “These results confirm that our unique resorbable magnesium technology does not share the same concerns as PLLA scaffolds, and does and will continue to play a significant role in vascular therapy. We believe in absorbable magnesium technology and patient care and see growing adoption within the medical community.“

Source CardiovascularNews

Duc Tin Clinic

Chia sẽ qua facebook bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Chia sẽ qua google bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Chia sẽ qua twitter bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Chia sẽ qua MySpace bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Chia sẽ qua LinkedIn bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Chia sẽ qua stumbleupon bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Chia sẽ qua icio bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Chia sẽ qua digg bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Chia sẽ qua yahoo bài: BIOSOLVE-IV data offer reassurance over rates of scaffold thrombosis from Magmaris bioresorbable scaffold

Tin tức liên quan

Enrolment reaches midway point in trial of Early Bird bleed monitoring system

Eight-fold increased risk of heart attack seen in patients with subclinical obstructive coronary atherosclerosis

ACC 2023: REVIVED-BCIS-2 results challenge “long-held beliefs” on myocardial viability testing prior to PCI

Blood pressure successfully cut in RADIANCE II ultrasound renal denervation trial

New data examine mortality rates and cardiac damage in early-stage aortic stenosis patients

SUPPORT CONSULTANT

Make an Appointment

I am Nguyen Thanh Sang, born in 1990. Since the examination and treatment at the clinic Duc Tin, I am very grateful to the Doctor for explaining and sharing about my illness. During the treatment time in the clinic I was very caring staff of the clinic. Now my illness has improved in a good way. Expect more and more clinic to be able to save many patients.

I sincerely thank you !. Tel: 0938303275

Huynh Thi Muoi, born in 1940, was examined and treated at Duc Tin Clinic. I am very pleased about how to serve and care patients of the clinic. The doctor is committed to explaining and sharing with the patient.

Huynh Thi Muoi sincerely thank you! Phone number: 0972868746

As I said Duc Tin surgical clinin is where my family trust, hope to visit. Physicians caring, thoughtful, gentle to the patient. Nurses and staff clinic polite, cheerful and thoughtful. This clinic clean, sterile, so I would love to. Tel: +84949914060.

The doctor is very caring, attentive and very gentle nurse, courteous, affable with me. The clinic is clean, comfortable, polite. I enjoyed this faith. Every visit I was very relieved disease. Tel: 0839820792.

I was patient, had to clinics of Dr. Le Duc Tin. I see very conscientious doctor patient care, answer any questions and very dedicated staff from the receptionist to the children tested, nursing. Clinics very clean and spacious. I'm very satisfied. Tel: +841227880829.